Xlife Sciences AGXSWX:XLS -11.06%50 Gross Margin % is 224.05% as of Dec. 2025, which is 545% above its 10-year median of 34.76. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 738 Biotechnology companies, Xlife Sciences AG ranks worse than 91.6% on this metric.
The historical rank and industry rank for Xlife Sciences AG's Gross Margin % or its related term are showing as below:
XSWX:XLS'
s Gross Margin % Range Over the Past 10 Years
Min: -6.55 Med: 34.76 Max: 65.87
Current: 3.27
During the past 8 years, the highestGross Margin % of Xlife Sciences AG was 65.87%. The lowest was -6.55%. And the median was 34.76%.
XSWX:XLS's Gross Margin % is ranked worse than 91.6% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs XSWX:XLS: 3.27
Xlife Sciences AG had a gross margin of 224.05% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Xlife Sciences AG was 0.00% per year.
Xlife Sciences AG (XSWX:XLS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Xlife Sciences AG had a gross margin of 224.05% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Xlife Sciences AG Gross Margin % Related Terms
Xlife Sciences AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Xlife Sciences AG (XSWX:XLS) has a Gross Margin % of 224.05% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Xlife Sciences AG and its competitors. This is 545% above median its historical median of 34.76. According to the industry distribution chart, Xlife Sciences AG ranks #676 out of 738 companies in the Biotechnology industry, placing it in the top 91.6%.
Is Xlife Sciences AG's Gross Margin % too high?
Xlife Sciences AG's current Gross Margin % of 224.05% is 545% above median its 10-year median of 34.76. The Biotechnology industry median Gross Margin % is 60.94. Xlife Sciences AG's value of 224.05% is 267.7% above this industry median. Based on the distribution chart, Xlife Sciences AG ranks #676 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #676 out of 738 companies for Gross Margin %. This places Xlife Sciences AG in the lower half of its industry. The industry median Gross Margin % is 60.94. Xlife Sciences AG's value of 224.05% is 267.7% above this benchmark. While the company's 10-year median is 34.76 vs. the industry median of 60.94, Xlife Sciences AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Gross Margin % of 224.05% is 267.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Gross Margin % is 224.05%, which is 545% above median its own 10-year median of 34.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Gross Margin % is 224.05%, which is 545% above median its 10-year median of 34.76 and 267.7% above the Biotechnology industry median of 60.94. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Gross Margin % is 224.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Gross Margin %: 224.05% (545% above median its 10-year median of 34.76)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
Industry Position: 267.7% above the Biotechnology median (#676 of 738)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
